In a phase 2 double-blind trial, psilocybin, a synthetic compound found in psychedelic mushrooms, was investigated for its potential in treating treatment-resistant depression. Adults with this condition were randomly assigned to receive a single dose of psilocybin at 25 mg, 10 mg, or a 1 mg control, alongside psychological support. The study found that the […]